EQUITY.GURU podcast - Investing for millennials and madmen

EQUITY.GURU
  • 3.3 (3)
  • INVESTING

Equity.Guru's Chris Parry and his expert journalism team talk to business leaders, executives and investors about opportunities in North America and beyond.

Episodes

  1. Short and Sweet (Ep 1) Brigadier Gold (BRG.V), PredictMedix (PMED.C), EarthRenew (ERTH.C) - The Jody Vance Experience

    12/05/2020

    Short and Sweet (Ep 1) Brigadier Gold (BRG.V), PredictMedix (PMED.C), EarthRenew (ERTH.C) - The Jody Vance Experience

    Welcome once again to Equity Guru’s Short and Sweet where we distill our in-depth interviews into solid nuggets of gold, enabling you to drink down the cream of each conversation in one delectable 5-minute gulp. In this week’s three-part episode, we are drawing from The Jody Vance Experience where Jody speaks with Brigadier Gold (BRG.V) president, CEO and director, Ranjeet Sundher, PredictMedix (PMED.C) CEO, Dr. Rahul Kushwah and EarthRenew (ERTH.C) CEO and director, Keith Driver. Listen in!   Full disclosure: Brigadier Gold, PredictMedix and EarthRenew are Equity.Guru marketing clients.

    19 min

  2. 11/23/2020

    Aequus Pharmaceuticals (AQS.V) CEO, Doug Janzen - EG Interview Highlights

    Developing new prescription medicine for market is a costly and oftentimes, a futile endeavor as drugmakers can spend up to $2.6 billion only to see 12% of their candidates gain approval. When Pfizer fails on two out of three new drugs, retail investors have grown leery of the space, but companies like Aequus Pharmaceuticals (AQS.V) have found a way to bypass this massive regulatory and financial bottleneck by seeking out existing drugs approved in other countries and bringing them to Canada for market approval. Spending 12-18 months rather than the standard 8-10 years for new drug approval, Aequus also benefits from low fixed costs that allow the company to profitably operate in a relatively small marketplace such as Canada in niche areas including neurology, ophthalmology and transplant. Positioned for growth with $2.0 million cash in the till, Aequus is a steady bet in an uncertain industry. As such, Equity Guru’s own Chris Parry spoke with company CEO and chairman, Doug Janzen, to get a better look at Aequus unique de-risked approach and its potential for investors. Here are the highlights!

    7 min

  3. 11/23/2020

    Aequus Pharmaceuticals (AQS.V) CEO, Doug Janzen - EG Interview Part 2

    Welcome to the second installment! Developing new prescription medicine for market is a costly and oftentimes, a futile endeavor as drugmakers can spend up to $2.6 billion only to see 12% of their candidates gain approval. When Pfizer fails on two out of three new drugs, retail investors have grown leery of the space, but companies like Aequus Pharmaceuticals (AQS.V) have found a way to bypass this massive regulatory and financial bottleneck by seeking out existing drugs approved in other countries and bringing them to Canada for market approval. Spending 12-18 months rather than the standard 8-10 years for new drug approval, Aequus also benefits from low fixed costs that allow the company to profitably operate in a relatively small marketplace such as Canada in niche areas including neurology, ophthalmology and transplant. Positioned for growth with $2.0 million cash in the till, Aequus is a steady bet in an uncertain industry. As such, Equity Guru’s own Chris Parry spoke with company CEO and chairman, Doug Janzen, to get a better look at Aequus unique de-risked approach and its potential for investors. Listen in!

    20 min

  4. 11/23/2020

    Aequus Pharmaceuticals (AQS.V) CEO, Doug Janzen - EG Interview Part 1

    Developing new prescription medicine for market is a costly and oftentimes, a futile endeavor as drugmakers can spend up to $2.6 billion only to see 12% of their candidates gain approval. When Pfizer fails on two out of three new drugs, retail investors have grown leery of the space, but companies like Aequus Pharmaceuticals (AQS.V) have found a way to bypass this massive regulatory and financial bottleneck by seeking out existing drugs approved in other countries and bringing them to Canada for market approval. Spending 12-18 months rather than the standard 8-10 years for new drug approval, Aequus also benefits from low fixed costs that allow the company to profitably operate in a relatively small marketplace such as Canada in niche areas including neurology, ophthalmology and transplant. Positioned for growth with $2.0 million cash in the till, Aequus is a steady bet in an uncertain industry. As such, Equity Guru’s own Chris Parry spoke with company CEO and chairman, Doug Janzen, to get a better look at Aequus unique de-risked approach and its potential for investors. Tune in!

    26 min
  • 4 Episodes

Ratings & Reviews

3.3
out of 5
3 Ratings

About

Equity.Guru's Chris Parry and his expert journalism team talk to business leaders, executives and investors about opportunities in North America and beyond.

Information